Biosergen AB (BIOSGN.ST) Research

Biosergen AB is a biopharmaceutical company specializing in the creation of antifungal medications. Its key development initiative is BSG005, an experimental antifungal drug candidate engineered to treat critical invasive fungal infections. The firm was established in 2004 and operates from its headquarters located in Solna, Sweden.

Market snapshot

Symbol
BIOSGN.ST
Price
$7.55
Day change
0.00%
Market cap
$17.7M
P/E ratio
-0.43x
52-week range
7.5-65.8
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Active Biotech AB (publ) (ACTI.ST)
  • Arcoma AB (ARCOMA.ST)
  • Biovica International AB (publ) (BIOVIC-B.ST)
  • Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)
  • Nanologica AB (publ) (NICA.ST)
  • NextCell Pharma AB (NXTCL.ST)
  • Pila Pharma AB (publ) (PILA.ST)
  • SciBase Holding AB (publ) (SCIB.ST)

Open Biosergen AB (BIOSGN.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.